Wake Forest NeuroNext Clinical Site (WAKENN)
维克森林 NeuroNext 临床站点 (WAKENN)
基本信息
- 批准号:10744928
- 负责人:
- 金额:$ 42.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-15 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAlabamaAlzheimer&aposs DiseaseAlzheimer&aposs Disease Core CenterAmericanAwardBaptist ChurchCapsicumCaringCell TherapyChildhoodClinicalClinical ResearchClinical SciencesClinical TrialsCohort StudiesCollaborationsConduct Clinical TrialsCountryDataData Coordinating CenterDedicationsDevelopmentDistrict of ColumbiaEconomically Deprived PopulationEnrollmentEnsureEthnic OriginFacultyFellowshipFellowship ProgramFemaleFundingFutureGene therapy trialGeneral PractitionersGeographyGoalsGrowthHealthHealth SciencesHealth systemHeart AtriumHispanicHomeHospitalsIncentivesInfrastructureInstitutionInterdisciplinary StudyLeadLeadershipLearningLocationMentorsMentorshipMinority EnrollmentMissionMulti-Institutional Clinical TrialNeurologistNeurologyNeurosciencesNorth CarolinaOccupational activity of managing financesParticipantPatient CarePatientsPediatric HospitalsPediatric NeurologyPerformancePersonsPopulation HeterogeneityPositioning AttributeProceduresProcessProtocols documentationPublic HealthRare DiseasesRegenerative MedicineReportingReproducibilityResearchResearch DesignResearch InfrastructureResearch PersonnelResourcesSecureSiteSolidSouth CarolinaSoutheastern United StatesSpecialistSpecimenSystemTherapeutic StudiesTrainingTraining ProgramsTranslational ResearchUnderrepresented PopulationsUnderserved PopulationUnited StatesUniversitiesWomancareercareer developmentclinical epidemiologyclinical research siteclinical trial participantdata integritydata managementdesigndrug discoveryexperienceforestgene therapyimprovedinfrastructure developmentmedical schoolsminority patientmultidisciplinarynervous system disordernext generationnovel strategiesorganizational structureoutreachparticipant enrollmentpatient retentionpeerpre-clinicalprogramsrecruitremote consentsenior facultysocioeconomic disadvantagesuccesstranslational pipelinetranslational scientist
项目摘要
AAtrium Health Wake Forest Baptist (AHWFB) has been a NeuroNEXT clinical site (“WAKENN”) since 2018. During our initial funding, WAKENN has been a consistently strong contributor to the NeuroNEXT Network (NN). We have rapidly launched the 3 NN studies available during this 5-year period. We have been a high enroller (N=19) – even being asked to stop enrollment in NN110 to “let other sites have the opportunity to enroll”. Diversity of enrolled participants demonstrates our ability to recruit underrepresented populations; 58% were either female, non-white or Hispanic ethnicity (e.g. 36% were women, 21% were non-white, and 5% were Hispanic). Our other performance metrics are also above average compared to other network sites. WAKENN has a vibrant fellowship. A unique success for WAKENN was the launch of the Wake Investigator Network Development (WIND) to support NN fellows in enhanced training and networking for multi- disciplinary collaboration to advance clinical research and clinical trials. Three fellows (to date) have completed the fellowship program; two have secured independent research funding. During this funding period, the WAKENN clinical footprint has grown considerably because of our partnership with Atrium Health (now 40-hospital health system). This offers new opportunities for collaboration, dissemination, and outreach to underrepresented patients and access to multidisciplinary investigators. We now have two children's hospitals, Brenner’s and Levine Children's Hospital (LCH). LCH is the largest children's hospital between Atlanta and Washington DC, with a catchment of more than 3.5 million. We have clinical experience with gene therapy, active participation in gene therapy trials, and preclinical expertise in gene therapy drug discovery. Our success is because of our dedicated leadership (Ezzeddine, Strowd, Duncan, Munger Clary) and committed team (Sissine, Burgos) and is backed with strong commitments from our department, institution, and the entire Atrium Health system which sees WAKENN as an enterprise-wide priority. This is backed with a solid institutional commitment to meet resource needs as they arise. Our established and active organizational structure, our expertise, and institutional commitment will ensure another successful funding period. We will meet the following aims: AIM 1: To continue to leverage our geographically, ethnically, and economically diverse catchment to effectively enroll and retain clinical trial participants from historically underserved populations. AIM 2: To employ and integrate clinical trial outreach infrastructure across our expanded health enterprise to promote rare and ultra-rare disease NN trials. AIM 3: To leverage the clinical research resources of our integrated academic health enterprise to incentivize, coordinate, and transparently track clinical trial creation, growth, and implementation. AIM 4: To continue to recruit and train the next generation of neuroscience researchers to design and implement meaningful and reproducible trials.
AATrium Health维克森林浸信会(AHWFB)自2018年以来一直是NeuroNEXT临床研究中心(“WAKENN”)。在我们最初的资助期间,WAKENN一直是NeuroNEXT网络(NN)的强大贡献者。在这5年期间,我们迅速启动了3项NN研究。我们的入组人数一直很高(N=19)-甚至被要求停止NN 110的入组,以“让其他研究中心有机会入组”。招募参与者的多样性表明我们有能力招募代表性不足的人群; 58%为女性、非白人或西班牙裔(例如36%为女性,21%为非白人,5%为西班牙裔)。与其他网络站点相比,我们的其他性能指标也高于平均水平。WAKENN拥有充满活力的奖学金。WAKENN的一个独特的成功是推出了Wake Investigator Network Development(WIND),以支持NN研究员加强培训和建立多学科合作网络,以推进临床研究和临床试验。三名研究员(到目前为止)已经完成了奖学金计划;两名获得了独立的研究资金。在此资助期间,由于我们与Atrium Health(现在有40家医院的医疗系统)的合作,WAKENN的临床足迹大幅增长。这为合作、传播和推广代表性不足的患者以及接触多学科研究人员提供了新的机会。我们现在有两个儿童医院,布伦纳和莱文儿童医院(LCH)。LCH是亚特兰大和华盛顿之间最大的儿童医院,有超过350万的病人。我们拥有基因治疗的临床经验,积极参与基因治疗试验,以及基因治疗药物发现的临床前专业知识。我们的成功归功于我们专注的领导层(Ezzeddine、Strowd、邓肯、Munger Clary)和忠诚的团队(Sissine、Burgos),并得到我们部门、机构和整个Atrium Health系统的坚定承诺的支持,该系统将WAKENN视为整个企业的优先事项。这得到了坚实的机构承诺的支持,以满足出现的资源需求。我们建立的积极的组织结构、我们的专业知识和机构承诺将确保另一个成功的供资期。我们将实现以下目标:目标1:继续利用我们的地理,种族和经济多样化的流域,有效地招募和保留临床试验参与者从历史上服务不足的人群。目标2:在我们扩大的卫生事业中使用和整合临床试验外展基础设施,以促进罕见和超罕见疾病NN试验。目标3:利用我们的综合学术健康企业的临床研究资源来激励,协调和透明地跟踪临床试验的创建,增长和实施。目标4:继续招募和培训下一代神经科学研究人员,以设计和实施有意义的和可重复的试验。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mustapha Ahmad Ezzeddine其他文献
Mustapha Ahmad Ezzeddine的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mustapha Ahmad Ezzeddine', 18)}}的其他基金
NINDS Stroke Trials Network - Regional Coordinating Center
NINDS 中风试验网络 - 区域协调中心
- 批准号:
8739334 - 财政年份:2013
- 资助金额:
$ 42.63万 - 项目类别:
NINDS Stroke Trials Network - Regional Coordinating Center
NINDS 中风试验网络 - 区域协调中心
- 批准号:
8895432 - 财政年份:2013
- 资助金额:
$ 42.63万 - 项目类别:
NINDS Stroke Trials Network - Regional Coordinating Center
NINDS 中风试验网络 - 区域协调中心
- 批准号:
8661881 - 财政年份:2013
- 资助金额:
$ 42.63万 - 项目类别:
NINDS Stroke Trials Network - Regional Coordinating Center
NINDS 中风试验网络 - 区域协调中心
- 批准号:
9118354 - 财政年份:2013
- 资助金额:
$ 42.63万 - 项目类别:
相似海外基金
Alabama Agricultural and Mechanical University ALSAMP Bridge to the Doctorate: Navigating BD Scholars’ Successful Transition to STEM Graduate Programs
阿拉巴马农业机械大学 ALSAMP 通往博士学位的桥梁:引导 BD 学者成功过渡到 STEM 研究生项目
- 批准号:
2404955 - 财政年份:2024
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
Conference: Second Joint Alabama--Florida Conference on Differential Equations, Dynamical Systems and Applications
会议:第二届阿拉巴马州-佛罗里达州微分方程、动力系统和应用联合会议
- 批准号:
2342407 - 财政年份:2024
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
IUCRC Planning Grant The University of Alabama: Center to Accelerate Recipe Development for Additive Manufacturing of Metals (CARDAMOM)
IUCRC 规划拨款阿拉巴马大学:加速金属增材制造配方开发中心 (CARDAMOM)
- 批准号:
2333363 - 财政年份:2024
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
RAPID: DRL AI: A Career-Driven AI Educational Program in Smart Manufacturing for Underserved High-school Students in the Alabama Black Belt Region
RAPID:DRL AI:针对阿拉巴马州黑带地区服务不足的高中生的智能制造领域职业驱动型人工智能教育计划
- 批准号:
2338987 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
Conference: Joint Alabama--Florida Conference on Differential Equations, Dynamical Systems and Applications
会议:阿拉巴马州-佛罗里达州微分方程、动力系统和应用联合会议
- 批准号:
2243027 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
Conference: HBCU Excellence in Research and EPSCoR Regional Outreach Workshop at Alabama State University (HERO-ASU)
会议:阿拉巴马州立大学 HBCU 卓越研究和 EPSCoR 区域外展研讨会 (HERO-ASU)
- 批准号:
2404231 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
RET Site: Engaging and Training Alabama STEM Teachers in Sensing Technologies
RET 网站:让阿拉巴马州 STEM 教师参与传感技术并对其进行培训
- 批准号:
2302144 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
Equipment: Facilitating Optical X-Ray Techniques for Research and Organized Training at Alabama State University (FOXTROT-ASU)
设备: 阿拉巴马州立大学 (FOXTROT-ASU) 促进光学 X 射线技术研究和组织培训
- 批准号:
2324575 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant
Louis Stokes Renewal STEM Pathways and Research Alliance: Alabama LSAMP
Louis Stokes 更新 STEM 途径和研究联盟:阿拉巴马州 LSAMP
- 批准号:
2308715 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Continuing Grant
NRT: Alabama Collaborative for Contemporary Education in Precision Timing (ACCEPT)
NRT:阿拉巴马州精密计时当代教育合作组织 (ACCEPT)
- 批准号:
2244074 - 财政年份:2023
- 资助金额:
$ 42.63万 - 项目类别:
Standard Grant